These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 19709408)

  • 1. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.
    Puppe J; Drost R; Liu X; Joosse SA; Evers B; Cornelissen-Steijger P; Nederlof P; Yu Q; Jonkers J; van Lohuizen M; Pietersen AM
    Breast Cancer Res; 2009; 11(4):R63. PubMed ID: 19709408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer.
    Wicha MS
    Breast Cancer Res; 2009; 11(5):108. PubMed ID: 19804613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.
    Gong C; Fujino K; Monteiro LJ; Gomes AR; Drost R; Davidson-Smith H; Takeda S; Khoo US; Jonkers J; Sproul D; Lam EW
    Oncogene; 2015 Sep; 34(39):5012-24. PubMed ID: 25531315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    Ratz L; Brambillasca C; Bartke L; Huetzen MA; Goergens J; Leidecker O; Jachimowicz RD; van de Ven M; Proost N; Siteur B; de Korte-Grimmerink R; Bouwman P; Pulver EM; de Bruijn R; Isensee J; Hucho T; Pandey G; van Lohuizen M; Mallmann P; Reinhardt HC; Jonkers J; Puppe J
    Breast Cancer Res; 2022 Jun; 24(1):41. PubMed ID: 35715861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
    Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
    Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 Is Overexpressed in
    Puppe J; Opdam M; Schouten PC; Jóźwiak K; Lips E; Severson T; van de Ven M; Brambillasca C; Bouwman P; van Tellingen O; Bernards R; Wesseling J; Eichler C; Thangarajah F; Malter W; Pandey GK; Ozretić L; Caldas C; van Lohuizen M; Hauptmann M; Rhiem K; Hahnen E; Reinhardt HC; Büttner R; Mallmann P; Schömig-Markiefka B; Schmutzler R; Linn S; Jonkers J
    Clin Cancer Res; 2019 Jul; 25(14):4351-4362. PubMed ID: 31036541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.
    Gonzalez ME; DuPrie ML; Krueger H; Merajver SD; Ventura AC; Toy KA; Kleer CG
    Cancer Res; 2011 Mar; 71(6):2360-70. PubMed ID: 21406404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.
    Bae WK; Yoo KH; Lee JS; Kim Y; Chung IJ; Park MH; Yoon JH; Furth PA; Hennighausen L
    Mol Carcinog; 2015 Oct; 54(10):1172-80. PubMed ID: 25043748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
    Li Y; Ren Y; Wang Y; Tan Y; Wang Q; Cai J; Zhou J; Yang C; Zhao K; Yi K; Jin W; Wang L; Liu M; Yang J; Li M; Kang C
    Theranostics; 2019; 9(16):4608-4623. PubMed ID: 31367244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
    Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
    Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
    Benoit YD; Laursen KB; Witherspoon MS; Lipkin SM; Gudas LJ
    J Cell Physiol; 2013 Apr; 228(4):764-72. PubMed ID: 23001792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
    Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
    Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
    Yan J; Ng SB; Tay JL; Lin B; Koh TL; Tan J; Selvarajan V; Liu SC; Bi C; Wang S; Choo SN; Shimizu N; Huang G; Yu Q; Chng WJ
    Blood; 2013 May; 121(22):4512-20. PubMed ID: 23529930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia.
    Li X; Gonzalez ME; Toy K; Filzen T; Merajver SD; Kleer CG
    Am J Pathol; 2009 Sep; 175(3):1246-54. PubMed ID: 19661437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.
    Gonzalez ME; Li X; Toy K; DuPrie M; Ventura AC; Banerjee M; Ljungman M; Merajver SD; Kleer CG
    Oncogene; 2009 Feb; 28(6):843-53. PubMed ID: 19079346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 is a negative modulator of the PRC2 complex.
    Wang L; Zeng X; Chen S; Ding L; Zhong J; Zhao JC; Wang L; Sarver A; Koller A; Zhi J; Ma Y; Yu J; Chen J; Huang H
    EMBO J; 2013 May; 32(11):1584-97. PubMed ID: 23624935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors.
    Bai F; Liu S; Liu X; Hollern DP; Scott A; Wang C; Zhang L; Fan C; Fu L; Perou CM; Zhu WG; Pei XH
    Breast Cancer Res; 2021 Jan; 23(1):10. PubMed ID: 33478572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.